vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and Scienture Holdings, Inc. (SCNX). Click either name above to swap in a different company.
Scienture Holdings, Inc. runs the higher net margin — 16668.9% vs -95337.1%, a 112006.0% gap on every dollar of revenue.
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
ASBP vs SCNX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $-168.7K |
| Net Profit | $-1.9M | $-28.1M |
| Gross Margin | 45.5% | 144.5% |
| Operating Margin | -59015.8% | 17487.0% |
| Net Margin | -95337.1% | 16668.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | -292.6% |
| EPS (diluted) | $-0.04 | $-1.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $-168.7K | ||
| Q3 25 | $1.9K | $590.0K | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $10.3K | ||
| Q3 24 | — | $64.9K | ||
| Q2 24 | — | $18.7K | ||
| Q4 23 | — | $111.7K | ||
| Q3 23 | — | $392.3K |
| Q4 25 | — | $-28.1M | ||
| Q3 25 | $-1.9M | $-3.6M | ||
| Q2 25 | — | $-6.7M | ||
| Q1 25 | — | $-3.1M | ||
| Q3 24 | — | $-3.2M | ||
| Q2 24 | — | $-1.8M | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-3.5M |
| Q4 25 | — | 144.5% | ||
| Q3 25 | 45.5% | 97.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 6.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | 10.1% |
| Q4 25 | — | 17487.0% | ||
| Q3 25 | -59015.8% | -739.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -34814.9% | ||
| Q3 24 | — | -5392.7% | ||
| Q2 24 | — | -7998.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -194.2% |
| Q4 25 | — | 16668.9% | ||
| Q3 25 | -95337.1% | -611.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -29869.3% | ||
| Q3 24 | — | -4908.3% | ||
| Q2 24 | — | -9807.5% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -898.6% |
| Q4 25 | — | $-1.70 | ||
| Q3 25 | $-0.04 | $-0.19 | ||
| Q2 25 | — | $-0.48 | ||
| Q1 25 | — | $-0.33 | ||
| Q3 24 | — | $-1.34 | ||
| Q2 24 | — | $-1.30 | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-4.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $6.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | $70.1M |
| Total Assets | $2.4M | $84.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $6.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | $361 | ||
| Q3 23 | — | $34.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.0M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $3.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | $70.1M | ||
| Q3 25 | $-11.5M | $82.7M | ||
| Q2 25 | — | $77.9M | ||
| Q1 25 | — | $81.2M | ||
| Q3 24 | — | $85.1M | ||
| Q2 24 | — | $11.8M | ||
| Q4 23 | — | $542.4K | ||
| Q3 23 | — | $11.6M |
| Q4 25 | — | $84.2M | ||
| Q3 25 | $2.4M | $104.8M | ||
| Q2 25 | — | $104.3M | ||
| Q1 25 | — | $106.4M | ||
| Q3 24 | — | $94.3M | ||
| Q2 24 | — | $14.8M | ||
| Q4 23 | — | $12.5M | ||
| Q3 23 | — | $21.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $-5.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.2M | ||
| Q3 25 | $-1.1M | $-3.2M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-3.0M | ||
| Q3 24 | — | $-5.4M | ||
| Q2 24 | — | $4.2M | ||
| Q4 23 | — | $-2.2M | ||
| Q3 23 | — | $-603.1K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-5.4M | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | -8325.7% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
